HPV, EBV, CMV, and HSV in Head and Neck Cancer: Molecular Detection, Seroprevalence, and Clinical Correlations

Basit Öğe Kaydı
dc.authorid0000-0002-6316-0517
dc.authorid0000-0003-0592-7297
dc.authorid0000-0001-9670-2426
dc.authorid0009-0002-1530-2047
dc.authorid0000-0003-3885-1620
dc.authorid0009-0005-5254-3773
dc.authorid0000-0002-2476-3796
dc.contributor.authorOnel, Mustafa
dc.contributor.authorKirkoyun Uysal, Hayriye
dc.contributor.authorUlusan, Murat
dc.contributor.authorAyeser, Utkucan
dc.contributor.authorSarsar, Kutay
dc.contributor.authorUcar, Yasemin Ayse
dc.contributor.authorYoldas, Ozlem
dc.date.accessioned2026-01-31T15:09:04Z
dc.date.available2026-01-31T15:09:04Z
dc.date.issued2025
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstract(1) Background: This study investigated the presence of human papillomavirus (HPV), HPV genotypes, Epstein-Barr virus (EBV), cytomegalovirus (CMV) and herpes simplex virus (HSV) in patients with Head and Neck Cancer (HNC) at both molecular and serological levels. (2) Methods Fifty patients with histopathologically confirmed HNC who were admitted to the Department of Otorhinolaryngology, Istanbul Faculty of Medicine. Viral DNA was detected using quantitative real-time PCR, and serological IgM and IgG antibodies were analyzed using the CMIA method; (3) Results: In blood samples, CMV and HSV DNA were not detected, whereas EBV DNA was identified in 2% and HPV DNA in 4% of patients. In tumor tissues, CMV DNA was detected in 8%, EBV DNA in 10%, and HPV DNA in 6%; HSV DNA is 6%. HPV genotypes 18, 45, and 69 were found in tissue samples. Serologically, IgG positivity for CMV, EBV, and HSV-1 exceeded 90%, whereas IgM positivity was low and not statistically significant; (4) Conclusions: HPV, EBV, and CMV DNA were detected at low frequencies in patients with HNC, while HSV DNA was absent. These findings underline the need for larger multi-center studies and support the consideration of routine viral screening, particularly for HPV, in specific tumor subtypes.
dc.description.sponsorshipScientific Research Projects Unit of Istanbul University [40491]
dc.description.sponsorshipThis study was financially supported by the Scientific Research Projects Unit of Istanbul University on 27 March 2024 (Project ID: 40491).
dc.identifier.doi10.3390/biology14111523
dc.identifier.issn2079-7737
dc.identifier.issue11
dc.identifier.pmid41300313
dc.identifier.scopus2-s2.0-105023496658
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org./10.3390/biology14111523
dc.identifier.urihttps://hdl.handle.net/20.500.12662/10813
dc.identifier.volume14
dc.identifier.wosWOS:001624102400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofBiology-Basel
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260128
dc.subjecthead and neck cancer
dc.subjectviral STD agents
dc.subjectoncogenic viruses
dc.titleHPV, EBV, CMV, and HSV in Head and Neck Cancer: Molecular Detection, Seroprevalence, and Clinical Correlations
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu